Introduction of New Leadership at Bridge to Life
Today marks an exciting milestone for Bridge to Life Ltd., a notable innovator in the realm of organ preservation solutions and perfusion technology, as they announce the appointment of Brian Lenz as Chief Financial Officer. Mr. Lenz comes aboard with over 20 years of robust leadership experience in various roles within the life sciences industry.
Brian Lenz's Experience and Contributions
Mr. Lenz has an impressive track record, having successfully raised over $1 billion through equity and debt financing over his career. This includes taking two companies public, demonstrating his strong proficiency in navigating the financial landscapes as CFO.
In addition to his prowess in financial management, Mr. Lenz has played critical roles in mergers and acquisitions and licensing transactions. His guided efforts have transformed organizations from research and development phases into profitable entities worth over $1 billion—an impressive leap from values below $100 million.
Leadership Dynamics at Bridge to Life
Expressing enthusiasm about Mr. Lenz's appointment, CEO Don Webber stated, "We are thrilled to welcome Brian to our executive leadership team. His previous role on the Board has established a strong connection based on trust and vision, which will be pivotal in our journey ahead. His energetic commitment to the future prospects of Bridge to Life, especially concerning the anticipated FDA clearance of VitaSmart™, is inspiring. With his expertise, we're poised to amplify the impact of our mission and solutions in the market."
Commitment to Growth and Innovation
Mr. Lenz shared his excitement during the announcement, stating, "Joining Bridge to Life represents an exciting opportunity to contribute to our growth. Having witnessed the company’s vibrant culture and innovation firsthand, especially in preparing for the launch of VitaSmart™, I am eager to work with Don and the management team. Together, we will strive to broaden access to viable donor organs on a global scale."
Mr. Lenz is expected to continue his influential role within the Board of Directors while engaging in his new executive responsibilities.
A Glimpse into Mr. Lenz's Professional Background
Prior to his strategic entrance at Bridge to Life, Mr. Lenz enhanced ADMA Biologics during his twelve-year tenure, where he served as Chief Financial Officer and General Manager of ADMA BioCenters. His earlier career includes holding the CFO and COO positions at CorMedix and other biotechnology firms. Initially, Mr. Lenz began his professional journey in audit at KPMG, and established a solid foundation as a licensed CPA. He holds a bachelor’s degree from Rider University and an MBA from St. Joseph's University.
About Bridge to Life Ltd.
Bridge to Life Ltd. stands as a leading market player in organ preservation, known for their top-notch products—including Belzer UW®, EasiSlush®, and the VitaSmart™ Hypothermic Oxygenated Perfusion System. The company prioritizes exceptional product quality and innovative solutions, collaborating with prominent Transplant Centers and Organ Procurement Organizations globally.
Currently, VitaSmart™ holds CE Marking and is available in various international markets. The company is looking forward to its FDA clearance in the near future, promising to enhance its presence in the United States.
Frequently Asked Questions
Who has been appointed as the Chief Financial Officer at Bridge to Life?
Brian Lenz has been appointed as the Chief Financial Officer at Bridge to Life Ltd.
What is Brian Lenz’s previous experience?
Brian Lenz has over 20 years of experience in the life sciences sector, including significant roles at ADMA Biologics and CorMedix.
What are Bridge to Life's key products?
The company's key products include Belzer UW®, EasiSlush®, and the VitaSmart™ Hypothermic Oxygenated Perfusion System.
What does VitaSmart™ offer?
VitaSmart™ aims to enhance organ preservation and is pending FDA clearance to open avenues in the United States market.
Where is Bridge to Life headquartered?
Bridge to Life Ltd. is based in a prominent location, serving various global markets to improve access to organ transplants.
